Details of the Drug Combination

General Information of Drug Combination (ID: DCTVX8C)

• Drug Combination Name: DFN-15 + Aminolevulinic Acid Hydrochloride
• Indication: Malignant melanoma; Status: Investigative [1]
• Component Drugs:
  DFN-15 (DM3BF9B): N.A.
  Aminolevulinic Acid Hydrochloride (DMWNHPC): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: LOX IMVI
  Zero Interaction Potency (ZIP) Score: 1.72
  Bliss Independence Score: 4.17
  Loewe Additivity Score: 7.5
  LHighest Single Agent (HSA) Score: 8.54

Molecular Interaction Atlas of This Drug Combination

Indication(s) of DFN-15

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Phase 3	[2]

Indication(s) of Aminolevulinic Acid Hydrochloride

Disease Entry	ICD 11	Status	REF
Actinic keratosis	EK90.0	Approved	[3]

Aminolevulinic Acid Hydrochloride Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Protoporphyrinogen oxidase (PPOX)	TTNFMS9	PPOX_HUMAN	Modulator	[4]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Carcinoma	DCV6Q9M	RXF 393	Investigative	[5]
Adenocarcinoma	DCR6PBH	OVCAR3	Investigative	[1]
Adenocarcinoma	DCR974N	A549	Investigative	[1]
Adenocarcinoma	DCGIN10	HT29	Investigative	[1]
Large cell lung carcinoma	DC6KSYC	NCI-H460	Investigative	[1]
Prostate carcinoma	DCJY69O	PC-3	Investigative	[1]

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165